Skip to content

Lamotrigine

Mood stabilizer • Brands: Lamictal

Last reviewed: 2025-09-23

General information

Indicated for: Lamotrigine extended-release tablets are indicated for: adjunctive therapy for primary generalized tonic-clonic seizures (PGTC) and partial-onset seizures with or without secondary generalization in patients aged 13 years and older. ( 1.1 ) conversion to monotherapy in patients aged 13 years and older with partial-onset seizures who are receiving treatment with a single antiepileptic drug. ( 1.2 ) Limitation of use: Safety and effectiveness in patients younger than 13 years have not been established. ( 1.3 )

Dosing & forms

  • Forms/strengths: —
  • Frequency: —
  • Food: —
  • Typical range: 100–400 mg/day (maintenance)

Mechanism (brief)

Blocks voltage-gated sodium channels; decreases glutamate release.

Metabolism & Half‑life

  • Metabolism: Hepatic glucuronidation (UGT1A4).
  • Half‑life: ~25–33 h (monotherapy).

Therapeutic Drug Monitoring (TDM)

Recommended: No

View labelExact

Monitoring highlights

  • Dermatologic (rash) — During titration

Sources